克拉屈滨、伊达比星、阿糖胞苷和维奈托克治疗急性髓性白血病、高危骨髓增生异常综合征或急变期慢性髓性白血病患者
克拉屈滨加伊达比星加阿糖胞苷 (ARAC) 治疗 AML、HR MDS 或 CML 成髓细胞期患者的 II 期研究
This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
研究概览
地位
条件
详细说明
Primary Objectives:
I. To determine the complete response rate (CR) of cladribine in combination with idarubicin and cytarabine (araC) in patients with acute myeloid leukemia (AML), high risk (HR) myelodysplastic syndrome (MDS), or myeloid blast phase of chronic myeloid leukemia (CML).
Secondary Objectives:
I. To determine the overall response rate (ORR) of cladribine in combination with idarubicin and araC in patients with AML, HR MDS, or myeloid blast phase of CML.
II. To assess overall survival (OS) and event free survival (EFS) of patients treated with cladribine, idarubicin, and araC (cytarabine).
III. To assess the duration of response to the combination in patients with AML, HR MDS, or myeloid blast phase of CML.
IV. To determine the safety and tolerability of the combination in patients with AML, HR MDS, or myeloid blast phase of CML.
Exploratory Objectives:
I. To study and describe the relationship between pretreatment patient/disease characteristics (including AML-associated molecular abnormalities) and outcome.
II. To identify molecular biomarkers predictive of response to therapy.
III. To study and describe the relationship between patient/disease characteristics, use of intrathecal prophylaxis, and incidence of leptomeningeal disease.
IV. To study the trajectories of leukemia mutations and molecular minimal residual disease (MRD) during the therapy.
OUTLINE:
INDUCTION: Patients receive cladribine intravenously (IV) and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax orally (PO) on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO twice daily (BID) on days 6-19 or gilteritinib PO once daily (QD) on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6-12 months.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Tapan Kadia
- 电话号码:713-792-7305
- 邮箱:tkadia@mdanderson.org
学习地点
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- M D Anderson Cancer Center
-
接触:
- Tapan M. Kadia
- 电话号码:713-792-7305
-
首席研究员:
- Tapan M. Kadia
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patients with a diagnosis of AML, Acute Biphenotypic Leukemia, or high risk MDS (>/= 10% blasts or IPSS >/= intermediate-2) will be eligible. Patients with CML in Myeloid Blast Phase are also eligible.
-
For Frontline cohort (1 or 4): No prior potentially-curative therapy for leukemia. Prior therapy with hydroxyurea, hematopoietic growth factors, azacytidine, decitabine, ATRA, or a total dose of cytarabine up to 2g (for emergency use for stabilization) is allowed. Patients deemed able to receive venetoclax (ie. insurance clearance) will be assigned to Frontline cohort 4. Patients with secondary AMLwho have been treated for their antecedent myeloid neoplasm will be enrolled into the separate Secondary AML cohort.
-
For Salvage cohort: Patients with previously treated, relapsed or refractory AML, Acute Biphenotypic Leukemia, or CML in Myeloid Blast Phase are eligible.
-
Age </= 65 years.
-
Adequate organ function as defined below:
- liver function (bilirubin < 2mg/dL, AST and/or ALT <3 x ULN - or <5 x ULN if related to leukemic involvement)
- kidney function (creatinine < 1.5 x ULN ).
- known cardiac ejection fraction of > or = 45% within the past 6 months
-
ECOG performance status of ≤ 2.
-
A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial.
-
Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient is required prior to their enrollment on the protocol.
Exclusion Criteria:
- Pregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided.
- Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (NYHA Class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patient with documented hypersensitivity to any of the components of the chemotherapy program.
- Men and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment (cladribine, cytarabine, idarubicin)
INDUCTION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given PO
其他名称:
Given PO
其他名称:
Given PO
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Complete response (CR) rate
大体时间:Up to 12 months
|
CR rate will be determined. |
Up to 12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall response rate (ORR)
大体时间:Up to 12 months
|
ORR will be determined. |
Up to 12 months
|
|
Overall survival (OS)
大体时间:Up to 12 months
|
OS will be assessed. |
Up to 12 months
|
|
Event-free survival (EFS)
大体时间:Up to 12 months
|
EFS will be assessed. |
Up to 12 months
|
|
Duration of response
大体时间:Up to 12 months
|
Duration of response will be assessed. |
Up to 12 months
|
|
Incidence of toxicities
大体时间:Up to 12 months
|
Safety and tolerability of cladribine in combination with idarubicin and cytarabine will be determined. |
Up to 12 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Use of intrathecal prophylaxis
大体时间:Up to 12 months
|
The relationship between patient/disease characteristics and use of intrathecal prophylaxis will be studied and described. |
Up to 12 months
|
|
Incidence of leptomeningeal disease
大体时间:Up to 12 months
|
The relationship between patient/disease characteristics and incidence of leptomeningeal disease will be studied and described. |
Up to 12 months
|
合作者和调查者
调查人员
- 首席研究员:Tapan M Kadia、M.D. Anderson Cancer Center
出版物和有用的链接
一般刊物
- Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug;8(8):e552-e561. doi: 10.1016/S2352-3026(21)00192-7.
- Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 Jun 20;36(18):1788-1797. doi: 10.1200/JCO.2017.77.6757. Epub 2018 Apr 27.
- Goulart H, Jabbour E, Short NJ, Kadia TM, Pemmaraju N, Takahashi K, Ravandi F, Konopleva M, Jain N. A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2025 Nov;25(11):800-807. doi: 10.1016/j.clml.2025.05.013. Epub 2025 May 20.
- Goulart H, Kantarjian H, Borthakur G, Daver N, DiNardo CD, Jabbour E, Pemmaraju N, Alvarado Y, Atluri H, Yilmaz M, Haddad FG, Marx KR, Rausch C, Loghavi S, Jain N, Garcia-Manero G, Ravandi-Kashani F, Kadia TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial. Cancer. 2025 Apr 15;131(8):e35840. doi: 10.1002/cncr.35840.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 病理过程
- 肿瘤
- 慢性病
- 疾病属性
- 免疫系统疾病
- 组织学类型的肿瘤
- 血液病
- 肿瘤过程
- 淋巴系统疾病
- 淋巴增生性疾病
- 免疫增生性疾病
- 白血病,骨髓
- 骨髓疾病
- 白血病、淋巴细胞
- 白血病
- 骨髓增生性疾病
- 细胞转化,肿瘤
- 致癌作用
- 病理状况、体征和症状
- 半身和淋巴疾病
- 白血病,骨髓,急性
- 骨髓增生异常综合征
- 白血病,骨髓性,慢性,BCR-ABL 阳性
- 爆炸危机
- 白血病,双表型,急性
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- 核酸,核苷酸和核苷
- 碳氢化合物
- 碳氢化合物,循环
- 碳水化合物
- 多环芳烃
- 碳氢化合物,芳香族
- 多环化合物
- 糖苷
- 嘌呤
- 胞苷
- 嘧啶核苷
- 嘧啶
- 核苷
- 核糖核苷
- 阿拉伯核苷
- 蒽环类动物
- 萘烯
- 氨基糖苷
- Daunorubicin
- 脱氧核糖核苷
- 2-氯腺苷
- 腺苷
- 嘌呤核苷
- 脱氧腺苷
- 阿糖胞苷
- 克拉屈滨
- 伊达比星
- Venetoclax
- 吉尔特替尼
- Midostaurin
其他研究编号
- 2012-0648
- 2012-0648 (其他标识符:M D Anderson Cancer Center)
- NCI-2014-01103 (注册表标识符:CTRP (Clinical Trial Reporting Program))
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.